Home/Filings/4/0001385508-23-000063
4//SEC Filing

Sinclair Michael 4

Accession 0001385508-23-000063

CIK 0001385508other

Filed

Mar 2, 7:00 PM ET

Accepted

Mar 3, 9:10 AM ET

Size

15.0 KB

Accession

0001385508-23-000063

Insider Transaction Report

Form 4
Period: 2023-03-02
Transactions
  • Disposition to Issuer

    Common Stock

    2023-03-02$20.00/sh27,450$549,0000 total(indirect: Footnote)
  • Disposition to Issuer

    Common Stock, par value $0.001 per share

    2023-03-02$20.00/sh22,720$454,4000 total
  • Disposition to Issuer

    Common Stock, par value $0.001 per share

    2023-03-02$20.00/sh40,000$800,0000 total
  • Disposition to Issuer

    Options

    2023-03-02100,0000 total
    Exercise: $8.00From: 2014-06-15Exp: 2024-06-14Common Stock, par value $0.001 per share (100,000 underlying)
  • Disposition to Issuer

    Options

    2023-03-02250,0000 total
    Exercise: $7.25From: 2015-10-27Exp: 2025-10-26Common Stock, par value $0.001 per share (250,000 underlying)
  • Disposition to Issuer

    Options

    2023-03-0275,0000 total
    Exercise: $6.00From: 2013-12-31Exp: 2023-12-30Common Stock, par value $0.001 per share (75,000 underlying)
Footnotes (3)
  • [F1]Disposed of pursuant to that certain Agreement and Plan of Merger between the Issuer, Indivior Inc., and Olive Acquisition Subsidiary, Inc., dated as of November 13, 2022 (the "Merger Agreement"), in exchange for a cash payment of $20.00 per share without interest thereon (the "Merger Consideration").
  • [F2]27,450 shares held in certificate form indirectly by (i) Proton Therapy USA, a entity owned jointly by Dr. Sinclair and his son (5,000 shares); (ii) one pension fund (10,000 shares); (iii) a second pension fund (2,000 shares); (iv) Clearsearch Ltd., an entity who holds the shares for the benefit of Dr. Sinclair (2,650 shares); and (v) Eastkings Pension Fund, an entity which holds the shares for the benefit of Dr. Sinclair's wife (7,800 shares).
  • [F3]The option was cancelled pursuant to the Merger Agreement, in exchange for a cash payment equal to (x) the difference between the Merger Consideration and the per share exercise price of the option, multiplied by (y) the number of disposed option shares.

Issuer

OPIANT PHARMACEUTICALS, INC.

CIK 0001385508

Entity typeother

Related Parties

1
  • filerCIK 0001551246

Filing Metadata

Form type
4
Filed
Mar 2, 7:00 PM ET
Accepted
Mar 3, 9:10 AM ET
Size
15.0 KB